A proton-pump inhibitor, rabeprazole, improves ventilatory function in patients with asthma associated with gastroesophageal reflux

Hirofumi Tsugeno, M. Mizuno, S. Fujiki, Hiroyuki Okada, M. Okamoto, Y. Hosaki, S. Ashlda, Fumihiro Mitsunobu, Y. Tanizaki, Y. Shiratori

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Background: Treatment of gastroesophageal reflux (GER) with proton-pump inhibitors (PPI) improves symptoms of asthma in some patients. However, the effects of a PPI on ventilatory function are still controversial. In this study, we measured ventilatory function in asthma patients treated with a PPI in order to identify those in whom a therapeutic effect on asthma can be expected from the acid suppression. Methods: From a cohort of 114 consecutive patients with bronchial asthma, 53 patients agreed to participate in the study and were treated with rabeprazole 20 mg daily for 8 weeks during an asymptomatic, stable period with no exacerbations of their asthma. Of the 53 patients, 22 were diagnosed as GER on the basis of the QUEST questionnaire and endoscopic examination. The patients were monitored for improvement in ventilatory function. Results: Four patients dropped out because of adverse drug reactions. All the patients with GER noted an improvement in reflux symptoms with PPI treatment. An improvement of more than 20% in peak expiratory flow (PEF) was observed in 8 of 21 GER patients but in none of the non-GER patients. Factors predictive of improvement in PEF with rabeprazole therapy were the QUEST score (odds ratio: 1.47, 95% CI: 1.06-2.04, P = 0.022) and steroid-dependency of asthma (odds ratio: 0.01, 95% CI: 0.001-0.31, P = 0.008). Conclusions: Treatment with rabeprazole is expected to ameliorate asthma in non-steroid-dependent patients who have symptomatic GER defined by the QUEST score.

Original languageEnglish
Pages (from-to)456-461
Number of pages6
JournalScandinavian Journal of Gastroenterology
Volume38
Issue number5
DOIs
Publication statusPublished - May 1 2003
Externally publishedYes

Fingerprint

Rabeprazole
Proton Pump Inhibitors
Gastroesophageal Reflux
Asthma
Odds Ratio
Therapeutic Uses
Therapeutics
Drug-Related Side Effects and Adverse Reactions

Keywords

  • Bronchial asthma
  • Gastro-esophageal reflux
  • Proton-pump inhibitor
  • QUEST questionnaire
  • Rabeprazole

ASJC Scopus subject areas

  • Gastroenterology

Cite this

A proton-pump inhibitor, rabeprazole, improves ventilatory function in patients with asthma associated with gastroesophageal reflux. / Tsugeno, Hirofumi; Mizuno, M.; Fujiki, S.; Okada, Hiroyuki; Okamoto, M.; Hosaki, Y.; Ashlda, S.; Mitsunobu, Fumihiro; Tanizaki, Y.; Shiratori, Y.

In: Scandinavian Journal of Gastroenterology, Vol. 38, No. 5, 01.05.2003, p. 456-461.

Research output: Contribution to journalArticle

Tsugeno, Hirofumi ; Mizuno, M. ; Fujiki, S. ; Okada, Hiroyuki ; Okamoto, M. ; Hosaki, Y. ; Ashlda, S. ; Mitsunobu, Fumihiro ; Tanizaki, Y. ; Shiratori, Y. / A proton-pump inhibitor, rabeprazole, improves ventilatory function in patients with asthma associated with gastroesophageal reflux. In: Scandinavian Journal of Gastroenterology. 2003 ; Vol. 38, No. 5. pp. 456-461.
@article{b7b4d165dccd4211b7643adefd2025da,
title = "A proton-pump inhibitor, rabeprazole, improves ventilatory function in patients with asthma associated with gastroesophageal reflux",
abstract = "Background: Treatment of gastroesophageal reflux (GER) with proton-pump inhibitors (PPI) improves symptoms of asthma in some patients. However, the effects of a PPI on ventilatory function are still controversial. In this study, we measured ventilatory function in asthma patients treated with a PPI in order to identify those in whom a therapeutic effect on asthma can be expected from the acid suppression. Methods: From a cohort of 114 consecutive patients with bronchial asthma, 53 patients agreed to participate in the study and were treated with rabeprazole 20 mg daily for 8 weeks during an asymptomatic, stable period with no exacerbations of their asthma. Of the 53 patients, 22 were diagnosed as GER on the basis of the QUEST questionnaire and endoscopic examination. The patients were monitored for improvement in ventilatory function. Results: Four patients dropped out because of adverse drug reactions. All the patients with GER noted an improvement in reflux symptoms with PPI treatment. An improvement of more than 20{\%} in peak expiratory flow (PEF) was observed in 8 of 21 GER patients but in none of the non-GER patients. Factors predictive of improvement in PEF with rabeprazole therapy were the QUEST score (odds ratio: 1.47, 95{\%} CI: 1.06-2.04, P = 0.022) and steroid-dependency of asthma (odds ratio: 0.01, 95{\%} CI: 0.001-0.31, P = 0.008). Conclusions: Treatment with rabeprazole is expected to ameliorate asthma in non-steroid-dependent patients who have symptomatic GER defined by the QUEST score.",
keywords = "Bronchial asthma, Gastro-esophageal reflux, Proton-pump inhibitor, QUEST questionnaire, Rabeprazole",
author = "Hirofumi Tsugeno and M. Mizuno and S. Fujiki and Hiroyuki Okada and M. Okamoto and Y. Hosaki and S. Ashlda and Fumihiro Mitsunobu and Y. Tanizaki and Y. Shiratori",
year = "2003",
month = "5",
day = "1",
doi = "10.1080/00365520310002490",
language = "English",
volume = "38",
pages = "456--461",
journal = "Scandinavian Journal of Gastroenterology",
issn = "0036-5521",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - A proton-pump inhibitor, rabeprazole, improves ventilatory function in patients with asthma associated with gastroesophageal reflux

AU - Tsugeno, Hirofumi

AU - Mizuno, M.

AU - Fujiki, S.

AU - Okada, Hiroyuki

AU - Okamoto, M.

AU - Hosaki, Y.

AU - Ashlda, S.

AU - Mitsunobu, Fumihiro

AU - Tanizaki, Y.

AU - Shiratori, Y.

PY - 2003/5/1

Y1 - 2003/5/1

N2 - Background: Treatment of gastroesophageal reflux (GER) with proton-pump inhibitors (PPI) improves symptoms of asthma in some patients. However, the effects of a PPI on ventilatory function are still controversial. In this study, we measured ventilatory function in asthma patients treated with a PPI in order to identify those in whom a therapeutic effect on asthma can be expected from the acid suppression. Methods: From a cohort of 114 consecutive patients with bronchial asthma, 53 patients agreed to participate in the study and were treated with rabeprazole 20 mg daily for 8 weeks during an asymptomatic, stable period with no exacerbations of their asthma. Of the 53 patients, 22 were diagnosed as GER on the basis of the QUEST questionnaire and endoscopic examination. The patients were monitored for improvement in ventilatory function. Results: Four patients dropped out because of adverse drug reactions. All the patients with GER noted an improvement in reflux symptoms with PPI treatment. An improvement of more than 20% in peak expiratory flow (PEF) was observed in 8 of 21 GER patients but in none of the non-GER patients. Factors predictive of improvement in PEF with rabeprazole therapy were the QUEST score (odds ratio: 1.47, 95% CI: 1.06-2.04, P = 0.022) and steroid-dependency of asthma (odds ratio: 0.01, 95% CI: 0.001-0.31, P = 0.008). Conclusions: Treatment with rabeprazole is expected to ameliorate asthma in non-steroid-dependent patients who have symptomatic GER defined by the QUEST score.

AB - Background: Treatment of gastroesophageal reflux (GER) with proton-pump inhibitors (PPI) improves symptoms of asthma in some patients. However, the effects of a PPI on ventilatory function are still controversial. In this study, we measured ventilatory function in asthma patients treated with a PPI in order to identify those in whom a therapeutic effect on asthma can be expected from the acid suppression. Methods: From a cohort of 114 consecutive patients with bronchial asthma, 53 patients agreed to participate in the study and were treated with rabeprazole 20 mg daily for 8 weeks during an asymptomatic, stable period with no exacerbations of their asthma. Of the 53 patients, 22 were diagnosed as GER on the basis of the QUEST questionnaire and endoscopic examination. The patients were monitored for improvement in ventilatory function. Results: Four patients dropped out because of adverse drug reactions. All the patients with GER noted an improvement in reflux symptoms with PPI treatment. An improvement of more than 20% in peak expiratory flow (PEF) was observed in 8 of 21 GER patients but in none of the non-GER patients. Factors predictive of improvement in PEF with rabeprazole therapy were the QUEST score (odds ratio: 1.47, 95% CI: 1.06-2.04, P = 0.022) and steroid-dependency of asthma (odds ratio: 0.01, 95% CI: 0.001-0.31, P = 0.008). Conclusions: Treatment with rabeprazole is expected to ameliorate asthma in non-steroid-dependent patients who have symptomatic GER defined by the QUEST score.

KW - Bronchial asthma

KW - Gastro-esophageal reflux

KW - Proton-pump inhibitor

KW - QUEST questionnaire

KW - Rabeprazole

UR - http://www.scopus.com/inward/record.url?scp=0038288719&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038288719&partnerID=8YFLogxK

U2 - 10.1080/00365520310002490

DO - 10.1080/00365520310002490

M3 - Article

C2 - 12795453

AN - SCOPUS:0038288719

VL - 38

SP - 456

EP - 461

JO - Scandinavian Journal of Gastroenterology

JF - Scandinavian Journal of Gastroenterology

SN - 0036-5521

IS - 5

ER -